GLP's ⏱ Half-life: ~5-7 days Phase 3

Pemvidutide

Pemvidutide (ALT-801)

Updated March 30, 2026

Evidence at a Glance

Regulatory statusPhase 3
Altimmune GLP-1/glucagon dual agonist; Phase 2b MASH complete, Phase 3 planned; not approved
Human evidenceModerate
Animal evidenceExtensive

Pemvidutide is an investigational GLP-1/glucagon dual agonist that completed the IMPACT Phase 2b MASH trial and Phase 2 obesity studies, received FDA Breakthrough Therapy Designation, and is advancing to a registrational Phase 3 program, but is not yet approved.

What the research does not support

  • It is not FDA-approved and cannot be legally marketed for obesity, MASH, or any condition.
  • Positive Phase 2b results are not proof of long-term benefit; the confirmatory Phase 3 trial has not reported.
  • Breakthrough Therapy Designation speeds review but is not an approval or a guarantee the drug will be approved.
  • It is a distinct molecule from semaglutide or tirzepatide and its outcomes cannot be assumed equivalent.
Half-Life
~5-7 days
Purity
Pharmaceutical grade (clinical trial material)
Mol. Weight
~4,100 Da
Form
Subcutaneous injection

What is Pemvidutide?

Pemvidutide (ALT-801) is being developed by Altimmune as a next-generation obesity therapeutic that specifically addresses the muscle loss problem inherent to GLP-1 monotherapy. By combining GLP-1 and glucagon receptor agonism, it aims to shift weight loss composition toward fat loss while preserving metabolically active lean tissue.

Dosage Information (Research Use)

Clinical trial doses: 1.2mg to 2.4mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Reconstitution & Handling

Clinical trial formulation.

Half-Life & Pharmacokinetics

~5-7 days

Reported Observations in Literature

Nausea, vomiting, diarrhea — similar GI profile to other GLP-1 RAs. Glucagon component may cause transient blood glucose elevations.

Key Research References

  • Altimmune press release. “MOMENTUM Phase 2 trial results.” 2023

How Pemvidutide Works

Pemvidutide is a balanced GLP-1/glucagon dual receptor agonist. The glucagon component enhances energy expenditure and hepatic fat oxidation while the GLP-1 component provides appetite suppression. This dual action preserves lean mass during weight loss — a critical advantage over GLP-1-only approaches where 25-40% of weight lost can be lean tissue.

Research Applications

🔬 Obesity with focus on body composition
🔬 NASH/MASH (metabolic liver disease)
🔬 Liver fibrosis

Research Findings

Phase 2 MOMENTUM trial showed 15.6% weight loss at 48 weeks with significantly better lean mass preservation compared to semaglutide-class agents. Also showed 72.9% relative reduction in liver fat, positioning it as a potential MASH therapeutic.

Dosage & Administration

Clinical trial doses: 1.2mg to 2.4mg subcutaneously once weekly. Not yet commercially available. Investigational compound.

Safety & Side Effects

Nausea, vomiting, diarrhea — similar GI profile to other GLP-1 RAs. Glucagon component may cause transient blood glucose elevations.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight ~4,100 Da
Half-Life ~5-7 days
Purity Pharmaceutical grade (clinical trial material)
Form Subcutaneous injection
Storage Refrigerate 2-8°C.

Key Research References

  • Altimmune press release. "MOMENTUM Phase 2 trial results." 2023

Related Peptides

View all →
Lixisenatide
GLP's
FDA-approved short-acting GLP-1 receptor agonist with unique postprandial glucose control properties.
View Profile →
Liraglutide
GLP's
FDA-approved once-daily GLP-1 receptor agonist researched for glycemic regulation and weight management.
View Profile →
Cagrilintide
GLP's
Long-acting amylin analog that suppresses appetite and enhances satiety, being developed as a complement to GLP-1 drugs for…
View Profile → Buy Now